Besides traditional (ACR/AER and eGFR) markers, some novel markers with higher sensitivity and better specificity, such as serum cystatin C, NGAL, L-FABP, and VEGF, should be used as routine evaluation indicators in the clinical management of DM. This evidence concerns the gene LCN2 and diabetes mellitus.